<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518310</url>
  </required_header>
  <id_info>
    <org_study_id>10351</org_study_id>
    <nct_id>NCT00518310</nct_id>
  </id_info>
  <brief_title>Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thorax National Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Chilena de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio de Salud Metropolitano Oriente, Ministerio de Salud de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thorax National Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a diffuse lung disease, associated with the&#xD;
      histological appearance of usual interstitial pneumonia (UIP), with an inexorably&#xD;
      deteriorating clinical course. Prognosis is poor, reported median survival is less than 3&#xD;
      years. The prevalence is estimated as being 3 to 10 per 100.000 in different Western&#xD;
      populations. To date, no pharmacological therapy has been proven to alter or reverse the&#xD;
      pathogenic process of IPF. Most treatments trials have been observational case series of&#xD;
      small patient populations and very few have been randomized, prospective and&#xD;
      placebo-controlled.&#xD;
&#xD;
      Two recent Cochrane reviews investigated the role of corticosteroids and other&#xD;
      immunomodulatory agents and concluded that there is no evidence for their use in IPF. Most&#xD;
      current therapies are targeted to suppress the inflammatory component of the disease, based&#xD;
      on the theory that it would be chronic alveolar inflammation which leads to parenchymal&#xD;
      remodeling and fibrosis. Recently, a hypothesis that has gained acceptance suggests that&#xD;
      fibrosis may result directly from alveolar injury, promoting an abnormal fibrogenic repair&#xD;
      mediated by fibroblasts and myofibroblasts.&#xD;
&#xD;
      One of the cytotoxic agents most widely used and better tolerated in the management of IPF is&#xD;
      azathioprine. Based upon limited data available and from a single small high quality&#xD;
      randomized controlled trial (RCT), this drug appears to confer, given in conjunction with&#xD;
      prednisone, a marginal long term survival advantage. Since this combination therapy is&#xD;
      associated serious adverse effect, we planned to design a trial of low dose corticosteroid&#xD;
      and azathioprine versus placebo in management of IPF, evaluating progression-free survival.&#xD;
&#xD;
      Our study hypothesis is: Combined therapy with azathioprine and corticosteroids improves&#xD;
      progression-free survival in patients with the diagnosis of IPF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will evaluate all adult patients consecutively referred from March 2005 to the Instituto&#xD;
      Nacional del Tórax (Thorax National Institute), Santiago, Chile for diagnostic evaluation of&#xD;
      Pulmonary Fibrosis. The routine evaluation will include, when indicated, the following steps:&#xD;
&#xD;
        -  History:&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Genre&#xD;
&#xD;
        -  Duration of symptoms before first consultation&#xD;
&#xD;
        -  Smoking status&#xD;
&#xD;
        -  Search for collagen vascular disease&#xD;
&#xD;
        -  Family history of pulmonary fibrosis&#xD;
&#xD;
        -  Occupational exposures&#xD;
&#xD;
        -  Drug ot toxic exposures&#xD;
&#xD;
        -  Physical examination: search of crackles and finger clubbing.&#xD;
&#xD;
        -  Laboratory data:&#xD;
&#xD;
        -  Complete blood bell count&#xD;
&#xD;
        -  BUN&#xD;
&#xD;
        -  Creatinine&#xD;
&#xD;
        -  Liver enzymes&#xD;
&#xD;
        -  Antinuclear antigens&#xD;
&#xD;
        -  Erythrocyte sedimentation rate&#xD;
&#xD;
        -  Rheumatoid factor&#xD;
&#xD;
        -  HIV&#xD;
&#xD;
        -  Antineutrophil cytoplasmic antibody (in appropiate clinical setting)&#xD;
&#xD;
        -  Antiglomerular basement antibody (in appropiate clinical setting)&#xD;
&#xD;
        -  Modified Medical Research Council Dyspnea Scale (MMRC) (10)&#xD;
&#xD;
        -  Chronic Respiratory Questionnaire (CRQ) (11)&#xD;
&#xD;
        -  Pulmonary function tests:&#xD;
&#xD;
        -  Spirometry&#xD;
&#xD;
        -  Plethismographic lung volumes&#xD;
&#xD;
        -  DLco&#xD;
&#xD;
        -  Composite physiologic index (12)&#xD;
&#xD;
        -  Exercise testing:&#xD;
&#xD;
        -  Six-Minute Walk Test (6MWT)&#xD;
&#xD;
        -  Resting and 6 minute SpO2&#xD;
&#xD;
        -  Presence or absence of desaturation to 88% or lower at the end of the six minute walk&#xD;
           (13)&#xD;
&#xD;
        -  Walked distance&#xD;
&#xD;
        -  Pre and post modified Borg dyspnea scores&#xD;
&#xD;
        -  Timed walk test (14)&#xD;
&#xD;
        -  Arterial blood gas analysis in rest and exercise, calculating the difference between&#xD;
           alveolar and arterial oxygen tension (P(A-a)O2) at rest and after exercise.&#xD;
&#xD;
        -  Radiologic studies:&#xD;
&#xD;
        -  Chest radiography&#xD;
&#xD;
        -  HRCT:&#xD;
&#xD;
        -  Definite or probable idiopathic pulmonary fibrosis (15):&#xD;
&#xD;
             -  Definitive criteria: presence of lung volume reduction, reticular abnormalities,&#xD;
                traction bronchiectasis, or both, with a basal and peripheral predominance; the&#xD;
                presence of honeycombing with a basal and peripheral predominance; and the absence&#xD;
                of atypical features of usual interstitial pneumonia - micronodules,&#xD;
                peribronchovascular nodules, consolidation, isolated (nonhoneycombing) cysts,&#xD;
                ground-glass attenuation (or if present, less extensive than the reticular&#xD;
                opacity), and mediastinal adenopathies (or if present, too limited to be visible on&#xD;
                a chest radiography).&#xD;
&#xD;
             -  Probable criteria: presence of a bilateral, predominantly basal and subpleural&#xD;
                reticular pattern with subpleural cysts (honeycombing), traction bronchiectasis, or&#xD;
                both in the absence of atypical features of UIP.&#xD;
&#xD;
        -  Scoring of the extent of lung fibrosis (16).&#xD;
&#xD;
        -  Bronchoscopy:&#xD;
&#xD;
        -  Bronchoalveolar lavage: cellular analysis and CD4/CD8 ratio.&#xD;
&#xD;
        -  Transbronchial biopsy.&#xD;
&#xD;
        -  Surgical lung biopsy:&#xD;
&#xD;
        -  Number&#xD;
&#xD;
        -  Site/Side&#xD;
&#xD;
        -  Type of surgery: open vs thoracoscopic&#xD;
&#xD;
        -  Histologic features (3)&#xD;
&#xD;
      Those patients with IPF diagnosed on the basis of clinical and radiographic criteria alone&#xD;
      according to the ATS/ERS consensus committee (3), and/or with a biopsy proven histological&#xD;
      pattern of UIP, will be selected to the randomization process, after they have signed the&#xD;
      written informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival, defined as free of death or a decrease from baseline in the FVC of at least 10%.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Exacerbations of IPF.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of life, measured with the Chronic Questionnaire (CRQ).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PO2 at rest and at exercise from baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P(A-a)O2 at rest and at exercise from baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicted FEV1 from baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second (FEV1) to FVC from baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plethysmographic lung volumes from baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion capacity for carbon monoxide (DLco) from baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-Minute Walk test, from baseline: resting and 6 minute SpO2, presence or absence of desaturation to 88% or lower at the end of the six minute walk, walked distance d. Pre and post modified Borg dyspnea scores</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring of extent of lung fibrosis on HRCT, according to two independent chest radiologists, form baseline.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse effects.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of protocol drop outs.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azathiprine Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZAPRED</intervention_name>
    <description>The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  45 and 79 years of age.&#xD;
&#xD;
          -  Clinical symptoms of IPF for at least 3 months.&#xD;
&#xD;
          -  Forced vital capacity (FVC) between 50 to 90% of the predicted value.&#xD;
&#xD;
          -  DLco at least 35% of the predicted value.&#xD;
&#xD;
          -  PaO2 &gt; 55 mm Hg while breathing ambient air at rest.&#xD;
&#xD;
          -  High-resolution computed tomography (HRCT) showing definite or probable criteria of&#xD;
             IPF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant exposure to known fibrogenic agents (birds, molds, hot tubes,&#xD;
             asbestos, radiation and drugs known to cause pulmonary fibrosis (amiodarone,&#xD;
             nitrofurantoin, bleomicin,etc)).&#xD;
&#xD;
          -  History of neurofibromatosis, Hermansky-Pudlak syndrome, metabolic storage disorders,&#xD;
             etc.&#xD;
&#xD;
          -  History of fever, weight loss, myalgias, arthralgias, skin rash, arthritis.&#xD;
&#xD;
          -  Active infection within one week before enrollment.&#xD;
&#xD;
          -  Alternative cause of interstitial lung disease.&#xD;
&#xD;
          -  Ratio of the forced expiratory volume in one second (VEF1) to FVC of less than 0.6&#xD;
             after the use of a bronchodilator.&#xD;
&#xD;
          -  Residual volume more than 120% of the predicted value (when available).&#xD;
&#xD;
          -  More than 20% of lymphocytes or eosinophils in bronchoalveolar lavage (BAL) (when&#xD;
             available).&#xD;
&#xD;
          -  Granulomas, infection or malignancy in the transbronchial or surgical biopsy (when&#xD;
             available).&#xD;
&#xD;
          -  Previous therapy with azathioprine, prednisolone (&gt;0.5 mg/kg/day or more for at least&#xD;
             3 months), cyclophosphamide or novel biotech drugs.&#xD;
&#xD;
          -  Unstable cardiovascular or neurologic disease.&#xD;
&#xD;
          -  Uncontrolled diabetes.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Lactation.&#xD;
&#xD;
          -  Likelihood of death, as predicted by the investigator, within the next year.&#xD;
&#xD;
          -  White cell blood count &lt; 4000/mm3.&#xD;
&#xD;
          -  Platelet count &lt; 100000/mm3.&#xD;
&#xD;
          -  Hematocrit &lt; 30% or &gt; 59%.&#xD;
&#xD;
          -  Liver enzymes more than 3 times the upper limit of the normal range.&#xD;
&#xD;
          -  Creatinine level &gt; 1.5 mg/dL.&#xD;
&#xD;
          -  Albumin level &lt; 3 g/dL.&#xD;
&#xD;
          -  Refusal to sign informed consent by patient or guardian.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florenzano Matías, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Las Condes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matias Florenzano, MD</last_name>
    <phone>056 9 8294435</phone>
    <email>mflorenzano@terra.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alvaro Undurraga, MD</last_name>
    <email>aundurragap@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional del Tórax</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannie Hinrichsen, RN</last_name>
      <email>jhinrichsen@torax.cl</email>
    </contact>
    <contact_backup>
      <last_name>Carmen L Naranjo</last_name>
      <email>cnaranjo@torax.cl</email>
    </contact_backup>
    <investigator>
      <last_name>Florenzano Matias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Undurraga Alvaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan C Rodríguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Navarro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Inzunza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariam Torres, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Sabbagh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan C Díaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Cavada, Stat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>August 16, 2007</last_update_submitted>
  <last_update_submitted_qc>August 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2007</last_update_posted>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>Usual interstitial pneumonia</keyword>
  <keyword>Cryptogenic fibrosing alveolitis</keyword>
  <keyword>Therapy</keyword>
  <keyword>Azathioprine</keyword>
  <keyword>Steroids</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

